PRIVERZhENNOST' ANTIDEMENTNOY TERAPII


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The problem of management of patients with dementia is highly relevant due to its high prevalence and a large social significance. Patients with cognitive disorders, however, have a very low treatment compliance, which greatly reduces effectiveness of therapy. Best treatment compliance is revealed among patients receiving memantine (Akatinol Memantine) due to its high therapeutic effect in cognitive disorders, and good tolerability.

Full Text

Restricted Access

About the authors

A. N Bogolepova

Email: annabogolepova@yandex.ru

References

  1. Zimmerman S., Sloane P.D., Reed D. Dementia prevalence and care in assisted living. Health Aff. (Millwood). 2014; 33(4): 658-66.
  2. Alzheimer's Disease International. World Alzheimer report 2013. www.alz.co.uk/research/world-report-2013
  3. Barnes D.E., Yaffe K. The Projected Impact of Risk Factor Reduction on Alzheimer's Disease Prevalence. Lancet Neurol. 2011; 10(9): 819-28.
  4. Гусев Е.И., Боголепова А.Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М., 2013. 160 c.
  5. Bond M., Rogers G., Peters J., et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol. Assessment. 2012; 16(21). Executive summary.
  6. Tifratene K., Duff F.L., Pradier C., et al. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer). Pharmacoepidemiol. Drug Saf. 2012; 21 (9): 1005-12.
  7. Haynes R.B., Ackloo E., Sahota N., McDonald H.P., Yao X. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews. 2008; (Issue 2): CD000011.
  8. Чернявская Т. Повышение комплаентности и качества жизни пожилых пациентов с артериальной гипертензией. Врач. 2010; 5: 20-5.
  9. Боголепова А.Н. Проблемы медикаментозной терапии больных с когнитивными нарушениями. Consilium medicum. 2012; 14(2): 18-22.
  10. Simpson S.H., Eurich D.T., Majumdar S.R., et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333: 15.
  11. McDonnell P.J., Jacobs M.R. Hospital admissions resulting from preventable adverse drug reactions. Ann. Pharmacother. 2002; 36: 1331-36.
  12. Yeaw J., Benner J.S., Walt J.G., Sian S., Smith D.B. Comparing adherence and persistence across 6 chronic medication classes. J. Manag. Care Pharm. 2009; 15(9): 728-40.
  13. Кузнецова Ю.И. Анализ приверженности амбулаторных больных к лечению // Bulletin of medical internet conferences. 2012; 2(Issue 2): 96.
  14. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organisation, 2003, http://whqlibdoc.who.int/publications/2003/9241545992.pdf
  15. Боголепова А.Н. Современные подходы к терапии цереброваскулярной патологии -пути повышения приверженности. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014 (в печати).
  16. Wallin A.K., Andreasen N., Eriksson S., et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord. 2007; 23: 150-160.
  17. Borah B., Sacco P., Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr. Med. Res. Opin. 2010; 26(8): 1957-65.
  18. Haider B., Schmidt R., Schweiger C., et al. Medication Adherence in Patients With Dementia: An Austrian Cohort Study. Alzheimer Dis Assoc Disord. 2013. Oct 9 [Epub ahead of print].
  19. Henley D.B., Sundell K.L., Sethuraman G., Schneider L.S. Adverse events and dropouts in Alzheimer's disease studies: What can we learn? Alzheimers Dement. 2014. Mar 6. pii: S1552-5260(13)02944-0.
  20. Brewer L., Bennett K., McGreevy C., Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur. J. Clin. Pharmacol. 2013; 69(7): 1467-75.
  21. Yeaw J., Benner J.S., Walt J.G., Sian S., Smith D.B. Comparing adherence and persistence across 6 chronic medication classes. J. Manag. Care Pharm. 2009; 15(9): 728-40.
  22. Mucha L., Shaohung S., Cuffel B., et al. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J. Manag. Care Pharm. 2008; 14(5): 451-61.
  23. Sicras-Mainar A., Vergara J., Leon-Colombo T., et al. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine. Rev. Neurol. 200; 43(8): 449-53.
  24. Gadzhanova S., Roughead L., Mackson J. Anticholinesterase duration in the Australian veteran population. Aust. N. Z. J. Psychiatry. 2010; 44(5): 469-74.
  25. Cruz Jentoft A.J., Hernаndez B. Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study. Neurologia. 2014; 29(1): 1-10.
  26. Stamouli S.S., Tzanakaki M., Giatas S., et al., Multicenter Observational Study for Patients with Alzheimer's Disease Treated with Memantine in the Clinical Practice. Dement Geriatr. Cogn Disord. Extra. 2011; 1: 10-19.
  27. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Dementia and Cognitive Improvement Group. 2006; (Issue 1): CD005593.
  28. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst. Reviews. 2006; (Issue 2): CD003154.
  29. Jones R.W. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int. J. Geriatr. Psychiatry. 2010; 25(6): 547-53.
  30. Rungsanpanya T., Muangpaisan W., Praditsuwan R. Clinical practice with antidementia drugs in a geriatric clinic. J. Med. Assoc. Thai. 2012; 95(8): 1081-89.
  31. Arlt S., Lindner R., Rösler A., von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008; 25(12): 1033-47.
  32. Förstl H., Stamouli S.S., Janetzky W., et al. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord. 2011; 32(4): 267-72.
  33. Calabrese P., Essner U., Förstl H. Memantine (Ebixa) in Clinical Practice - Results of an Observational Study. Dement Geriatr Cogn Disord. 2007; 24: 111-17.
  34. Wilkinson D., Wirth Y., Goebel C. Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response. Dement Geriatr Cogn Disord. 2014; 37(1-2): 71-85.
  35. Santaguida P.S., Raina P., Booker L., et al. Pharmacological Treatment of Dementia. Evidence Report/Technology Assessment No. 97 (Prepared by McMaster University Evidence-based Practice Center under Contract No. 290-02-0020). AHRQ Publication No. 04-E018-2. Rockville, MD: Agency for Healthcare Research and Quality. April, 2004.
  36. Grossberg G.T., Manes F., Allegri R.F. et al. The safety, tolerability and efficacy of once-daily memantine (28 mg): a multinationale, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013; 27: 469-78.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies